Technology evaluation: AAV factor IX gene therapy, Avigen Inc

Area of Science:

• Gene therapy
• Hematology
• Viral vector technology

Background:

• Hemophilia B is a serious bleeding disorder caused by a deficiency in Factor IX.
• Current treatments involve regular infusions of Factor IX concentrate.
• Novel therapeutic approaches, including gene therapy, are needed to improve patient outcomes.

Purpose of the Study:

• To evaluate the safety and preliminary efficacy of a recombinant adeno-associated viral vector (AAV-CMV-hF.IX) for hemophilia B treatment.
• To assess potential toxicity, germline transmission, and immune responses to the vector and Factor IX.

Main Methods:

• A Phase I clinical trial was conducted involving three patients with severe hemophilia B.
• Patients received a low-dose injection of the AAV-CMV-hF.IX vector (Coagulin-B).
• Safety assessments included monitoring for toxicity, germline transmission, and inhibitory antibodies.

Main Results:

• The AAV-CMV-hF.IX vector was found to be safe and well-tolerated in all three patients.
• No evidence of toxicity or germline transmission of vector sequences was observed.
• Two of the three patients showed a modest clinical response, indicating potential therapeutic benefit.

Conclusions:

• This study demonstrates the preliminary safety and tolerability of AAV-CMV-hF.IX gene therapy for hemophilia B.
• The observed clinical response suggests potential efficacy, warranting further investigation in larger trials.
• Gene therapy represents a promising avenue for the treatment of hemophilia B.